Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Nov 10;5(1):264.
doi: 10.1038/s41392-020-00383-5.

Therapeutic utility of immunosuppressive TREM2+ macrophages: an important step forward in potentiating the immune checkpoint inhibitors

Fulya Koksalar Alkan  1 , Hasan Korkaya  2   3
Affiliations
Comment

Therapeutic utility of immunosuppressive TREM2+ macrophages: an important step forward in potentiating the immune checkpoint inhibitors

Fulya Koksalar Alkan et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
TREM2 modulated immunosuppressive tumor microenvironment is an attractive therapeutic target that also potentiates the efficacy of ICIs. Tumor-infiltrated TREM2+ macrophages, characterized by CX3CR1hiMRC1lowCD83lowCXCL9low phenotype creates an TME which promotes aggressive properties on tumor cells while suppressing anti-tumor immune responses. Targeting the TREM2 by genetic ablation or anti-TREM2 antibody reverses the immunosuppressive TME and enhances the anti-tumor immune responses that eradicate tumors when combined with ICIs
See this image and copyright information in PMC

Comment on

  • TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy.
    Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, Brioschi S, Bugatti M, Omodei AS, Ricci B, Fronick C, Panda SK, Takeuchi Y, Gubin MM, Faccio R, Cella M, Gilfillan S, Unanue ER, Artyomov MN, Schreiber RD, Colonna M. Molgora M, et al. Cell. 2020 Aug 20;182(4):886-900.e17. doi: 10.1016/j.cell.2020.07.013. Epub 2020 Aug 11. Cell. 2020. PMID: 32783918 Free PMC article.

References

    1. Molgora M, et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell. 2020;182:886–900. doi: 10.1016/j.cell.2020.07.013. - DOI - PMC - PubMed
    1. Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30:507–519. doi: 10.1038/s41422-020-0337-2. - DOI - PMC - PubMed
    1. Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 2016;39:1–6. doi: 10.1016/j.coi.2015.10.009. - DOI - PMC - PubMed
    1. Deczkowska A, Weiner A, Amit I. The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell. 2020;181:1207–1217. doi: 10.1016/j.cell.2020.05.003. - DOI - PubMed
    1. Ouzounova M, et al. Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade. Nat. Commun. 2017;8:14979. doi: 10.1038/ncomms14979. - DOI - PMC - PubMed

Publication types

Substances